Takeda Sues 3 Rivals Over Planned Heartburn Drug Generics

Law360, New York (May 30, 2013, 1:46 PM EDT) -- Takeda Pharmaceutical Co. Ltd. on Wednesday sued Sandoz Inc. and two other rivals in California federal court, accusing their planned generic versions of acid reflux treatment Dexilant of infringing a patent for the drug.

According to Takeda, abbreviated new drug applications filed by generic drugmakers Sandoz, Impax Laboratories Inc. and TWi Pharmaceuticals Inc., seeking U.S. Food and Drug Administration approval to make and sell generic dexlansoprazole delayed-release capsules in 30 and 60 milligram dosage strengths, had infringed on U.S. Patent Number 8,173,158.

“Unless [the drugmakers are]...
To view the full article, register now.